Company research
Nyxoah SA
CIK 1857190Updated Sep 24, 2026
SecurityNYXH · NASDAQ · equity
NYXH price & chart
Loading TradingView…
NASDAQ:NYXH on TradingView ↗About the company
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · EURSource
Source
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossEUR | -90,085,000Source | -59,236,000Source | -43,212,000Source | -31,225,000Source |
| Additional Financial Items | ||||
| AdjustmentsForCurrentTaxOfPriorPeriodEUR | 14,000Source | -152,000Source | -1,622,000Source | 0Source |
| AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossEUR | 2,254,000Source | — | — | — |
| AdjustmentsForFinanceCostsEUR | 11,519,000Source | 5,070,000Source | 3,729,000Source | 4,320,000Source |
| AdjustmentsForFinanceIncomeEUR | 5,928,000Source | 7,447,000Source | 4,174,000Source | 6,763,000Source |
| AdjustmentsForSharebasedPaymentsEUR | 4,886,000Source | 3,968,000Source | 2,611,000Source | 2,698,000Source |
| InterestPaidClassifiedAsFinancingActivitiesEUR | 694,000Source | 496,000Source | 192,000Source | 130,000Source |
| InterestReceivedClassifiedAsOperatingActivitiesEUR | — | 0Source | 0Source | 3,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesEUR | 1,133,000Source | 1,208,000Source | 757,000Source | 772,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesEUR | — | 10,000,000Source | — | 0Source |
| ProceedsFromIssuingSharesEUR | 20,864,000Source | 69,722,000Source | 18,337,000Source | 255,000Source |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesEUR | 3,000Source | 7,000Source | — | — |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesEUR | 2,964,000Source | 4,907,000Source | 8,462,000Source | 15,463,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesEUR | — | 63,000Source | 83,000Source | 83,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseEUR | 48,261,000Source | 28,461,000Source | 21,687,000Source | 18,855,000Source |
| Total Revenue | — | — | — | — |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | 0.25Source | 0.25Source | 0.25Source | 0.25Source |
| AverageEffectiveTaxRatenumber | -0.01Source | -0.05Source | 0.03Source | -0.04Source |
| BasicEarningsLossPerShareEUR/shares | -2.36Source | -1.81Source | -1.55Source | -1.21Source |
| CurrentTaxExpenseIncomeEUR | 1,026,000Source | 2,811,000Source | -1,442,000Source | 1,179,000Source |
| DeferredTaxExpenseIncomeEUR | -31,000Source | -7,000Source | -3,000Source | -10,000Source |
| DepreciationRightofuseAssetsEUR | 1,200,000Source | 1,000,000Source | 800,000Source | — |
| DilutedEarningsLossPerShareEUR/shares | -2.36Source | -1.81Source | -1.55Source | -1.21Source |
| EmployeeBenefitsExpenseEUR | 40,741,000Source | 23,783,000Source | — | — |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesEUR | 4,886,000Source | 3,968,000Source | — | — |
| ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsedEUR | 198,000Source | 135,000Source | 202,000Source | 240,000Source |
| FinanceCostsEUR | 11,519,000Source | 5,070,000Source | 3,729,000Source | 4,320,000Source |
| FinanceIncomeEUR | 5,928,000Source | 7,447,000Source | 4,174,000Source | 6,763,000Source |
| GrossProfitEUR | 6,326,000Source | 2,969,000Source | 2,692,000Source | 1,934,000Source |
| IncomeTaxExpenseContinuingOperationsEUR | 1,009,000Source | 2,804,000Source | -1,445,000Source | 1,169,000Source |
| InterestExpenseOnLeaseLiabilitiesEUR | 121,000Source | 150,000Source | 129,000Source | 98,000Source |
| OtherEmployeeExpenseEUR | 632,000Source | 603,000Source | — | — |
| OtherOperatingIncomeExpenseEUR | 1,274,000Source | 1,008,000Source | 544,000Source | 283,000Source |
| PostemploymentBenefitExpenseDefinedBenefitPlansEUR | — | 190,000Source | 210,000Source | 260,000Source |
| PostemploymentBenefitExpenseDefinedContributionPlansEUR | 159,000Source | — | — | — |
| ProfitLossAttributableToOwnersOfParentEUR | -90,085,000Source | -59,236,000Source | -43,212,000Source | -31,225,000Source |
| ProfitLossBeforeTaxEUR | -89,076,000Source | -56,432,000Source | -44,657,000Source | -30,056,000Source |
| ProfitLossFromOperatingActivitiesEUR | -83,485,000Source | -58,809,000Source | -45,102,000Source | -32,499,000Source |
| ResearchAndDevelopmentExpenseEUR | 42,824,000Source | 34,325,000Source | 26,651,000Source | 15,861,000Source |
| RevenueFromInterestEUR | 1,834,000Source | 2,502,000Source | — | — |
Filing attachments
tm2625920d1_ex99-1.htm · 6-K · 2026-09-22
Exhibit 99.1 REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces Chief Financial Officer Transition Loïc Moreau, Nyxoah’s President International and former CFO, to serve as interim CFO Company reaffirms full year 2026 financial guidance Mont-Saint-Guibert, Belgium - September 21, 2026, 22:01h CET / 4:01h ET - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apn…
Read attachment ↗